8-K: Adagio Medical Receives Nasdaq Deficiency Notice

Adagio Medical Holdings, Inc. has been notified by Nasdaq of non-compliance with the minimum $1.00 bid price requirement.

Summary

• Adagio Medical received a formal notice from Nasdaq on June 12, 2026, regarding failure to maintain a minimum bid price of $1.00 per share.
• The company has 180 calendar days, until December 9, 2026, to regain compliance.
• Compliance is achieved if the stock price closes at or above $1.00 for at least ten consecutive business days during the grace period.
• The company's common stock continues to trade on the Nasdaq Capital Market during this period.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as it highlights downward pressure on the stock price and introduces regulatory uncertainty regarding the company's continued listing.

Positives

• The notification does not currently impact the listing status of the company's common stock.
• The company has a clear 180-day window to rectify the deficiency before facing potential delisting.

Negatives

• The company failed to maintain the minimum $1.00 bid price requirement for 30 consecutive business days.
• There is no guarantee that the company will be able to regain compliance within the allotted timeframe.

Risks

• Potential delisting from the Nasdaq Capital Market if compliance is not regained by December 9, 2026.
• Possible requirement to execute a reverse stock split to artificially inflate the share price to meet listing standards.
• Risk of failing to meet other Nasdaq listing criteria during the compliance period.

Future Outlook

The company is currently evaluating all available options to regain compliance with the Nasdaq listing rules, which may include a reverse stock split if necessary.

Industry Context

StockSavvy.ai notes that receiving a Nasdaq deficiency notice is a common challenge for small-cap and emerging growth medical technology companies facing market volatility, often necessitating strategic corporate actions to maintain exchange eligibility.

Comparison to Industry Standards

• The company is following standard Nasdaq regulatory procedures for price-based non-compliance.
• Many emerging growth companies in the medical device sector face similar listing hurdles during periods of capital market contraction.

Stakeholder Impact

• Shareholders face increased uncertainty regarding the stock's liquidity and exchange listing status.
• Potential for volatility as the company considers options to regain compliance.

Next Steps

• Monitor stock price performance to determine if organic growth can meet the $1.00 threshold.
• Evaluate the necessity of a reverse stock split to regain compliance before the December 9, 2026 deadline.

Key Dates

Recommendation

Investors should hold until the company clarifies its strategy for regaining compliance, as the risk of a reverse stock split or potential delisting creates significant near-term uncertainty.

Keywords

Adagio Medical, Nasdaq, Delisting, Bid Price, Compliance, ADGM